Document is current
Any future updates will be listed below
-
Authors
Sachsenweger, Juliane
Jansche, Rebecca
Merk, Tatjana
Heitmeir, Benedikt
Deniz, Miriam
Faust, Ulrike
Roggia, Cristiana
Tzschach, Andreas http://orcid.org/0000-0002-6840-965X
Schroeder, Christopher
Riess, Angelika
Pospiech, Helmut
Peltoketo, Hellevi
Pylkäs, Katri
Winqvist, Robert http://orcid.org/0000-0003-0932-9104
Wiesmüller, Lisa http://orcid.org/0000-0002-2397-5041
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (International Graduate School in Molecular Medicine Ulm, Germany, PO 1884/2-1)
Deutsche Krebshilfe (Priority Program ‘Translational Oncology’, project HerediVar´, 70114178)
PhD fellowship from International Graduate School in Molecular Medicine Ulm
Dr.med scholarship for Experimental Medicine from Medical Faculty of Ulm University
Else Kröner Fresenius Stiftung
Finnish Cancer Foundation Academy of Finland Sigrid Juselius Foundation
- License Information
-
More Information
Article History
Received: 6 October 2022
Revised: 27 April 2023
Accepted: 2 May 2023
First Online: 17 May 2023
Competing interests
: The authors declare no competing interests.
: The index patient ABR-1106 and her mother ABR-wt (Supplementary TableInternalRef removed) were counseled at the University Hospital of Tübingen, Germany and the index patient ABR-577 was counseled at the University Hospital of Freiburg, Germany, according to the guidelines of the German Consortium for HBOC. Written informed consent was obtained for scientific use (BRCA20006 173/2011BO2; HerediCaRe 505/2020BO; HerediVar 838/2021BO2). The study was performed in accordance with the Declaration of Helsinki.
